Compare
Omeros Corp vs Atea Pharmaceuticals, Inc. vs Keros Therapeutics, Inc. vs Zymeworks Inc.
| Latest fiscal year | Omeros Corp OMER | Atea Pharmaceuticals, Inc. AVIR | Keros Therapeutics, Inc. KROS | Zymeworks Inc. ZYME |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $244.06M | $105.97M |
| Revenue growth (YoY) | n/a | n/a | n/m | +38.9% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | 27.7% | -87.3% |
| Net margin | n/a | n/a | 35.7% | -76.6% |
| Net income | -$3.35M | -$158.35M | $87.01M | -$81.13M |
| EPS (Diluted) | -$0.05 | -$1.94 | $2.30 | -$1.08 |
| Operating cash flow | -$116.09M | -$132.03M | $107.50M | -$33.01M |
| Free cash flow | -$116.16M | n/a | $105.95M | -$34.53M |
| Cash & equivalents | $9.66M | $95.71M | $287.42M | $41.16M |
| Total assets | $325.63M | $315.22M | $338.02M | $346.53M |
| Total liabilities | n/a | $39.78M | $34.89M | $78.03M |
| Shareholders' equity | -$121.23M | $275.43M | $303.13M | $268.50M |
| Return on year-end equity | n/a | -57.5% | 28.7% | -30.2% |
| Shares outstanding | 71.67M | 78.13M | 19.54M | 74.64M |
Revenue, most recent five fiscal years
| Fiscal year | Omeros Corp | Atea Pharmaceuticals, Inc. | Keros Therapeutics, Inc. | Zymeworks Inc. |
|---|---|---|---|---|
| Latest | $73.81M Ended 2020-12-31 | $351.37M Ended 2021-12-31 | $244.06M Ended 2025-12-31 | $105.97M Ended 2025-12-31 |
| 1 year earlier | $111.81M Ended 2019-12-31 | $48.63M Ended 2020-12-31 | $3.55M Ended 2024-12-31 | $76.30M Ended 2024-12-31 |
| 2 years earlier | $29.87M Ended 2018-12-31 | n/a | $151.0K Ended 2023-12-31 | $76.01M Ended 2023-12-31 |
| 3 years earlier | $64.83M Ended 2017-12-31 | n/a | $0 Ended 2022-12-31 | $412.48M Ended 2022-12-31 |
| 4 years earlier | $41.62M Ended 2016-12-31 | n/a | $20.10M Ended 2021-12-31 | $26.68M Ended 2021-12-31 |